DE Burlo Group Inc. Sells 50 Shares of STERIS plc (NYSE:STE)

DE Burlo Group Inc. reduced its stake in shares of STERIS plc (NYSE:STE) by 1.3% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,750 shares of the medical equipment provider’s stock after selling 50 shares during the period. DE Burlo Group Inc.’s holdings in STERIS were worth $910,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of STE. Ashton Thomas Securities LLC acquired a new stake in STERIS during the 3rd quarter worth about $25,000. Central Pacific Bank Trust Division acquired a new stake in shares of STERIS in the 3rd quarter valued at about $28,000. Quent Capital LLC grew its stake in shares of STERIS by 112.7% in the 1st quarter. Quent Capital LLC now owns 134 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 71 shares during the period. Versant Capital Management Inc grew its stake in shares of STERIS by 2,262.5% in the 2nd quarter. Versant Capital Management Inc now owns 189 shares of the medical equipment provider’s stock valued at $41,000 after buying an additional 181 shares during the period. Finally, Brown Brothers Harriman & Co. grew its stake in shares of STERIS by 154.7% in the 2nd quarter. Brown Brothers Harriman & Co. now owns 191 shares of the medical equipment provider’s stock valued at $42,000 after buying an additional 116 shares during the period. 94.69% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently commented on the company. Stephens restated an “overweight” rating and issued a $260.00 target price on shares of STERIS in a research note on Thursday, November 7th. KeyCorp raised their target price on STERIS from $255.00 to $265.00 and gave the company an “overweight” rating in a research note on Tuesday, September 3rd. StockNews.com downgraded STERIS from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 29th. Piper Sandler upgraded STERIS from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $230.00 to $260.00 in a research note on Thursday, October 24th. Finally, JMP Securities reiterated a “market outperform” rating and set a $265.00 price target on shares of STERIS in a research note on Monday. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $253.00.

Insiders Place Their Bets

In other news, CFO Michael J. Tokich sold 23,332 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the sale, the chief financial officer now owns 42,930 shares in the company, valued at $10,603,710. This represents a 35.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 1.14% of the company’s stock.

STERIS Stock Up 0.1 %

Shares of NYSE:STE opened at $212.25 on Thursday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.55 and a current ratio of 2.41. The firm has a market capitalization of $20.95 billion, a PE ratio of 48.46 and a beta of 0.85. The firm has a fifty day moving average of $228.50 and a 200 day moving average of $228.58. STERIS plc has a 52-week low of $195.47 and a 52-week high of $248.24.

STERIS (NYSE:STE) last issued its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported $2.14 EPS for the quarter, beating the consensus estimate of $2.12 by $0.02. The firm had revenue of $1.33 billion during the quarter, compared to the consensus estimate of $1.33 billion. STERIS had a net margin of 8.02% and a return on equity of 13.78%. The company’s quarterly revenue was up 7.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.03 earnings per share. As a group, research analysts anticipate that STERIS plc will post 9.15 EPS for the current fiscal year.

STERIS Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 19th. Shareholders of record on Tuesday, November 19th will be issued a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a yield of 1.07%. The ex-dividend date is Tuesday, November 19th. STERIS’s dividend payout ratio (DPR) is presently 52.05%.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.